AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails - Zacks.com

AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails  Zacks.com

IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.



Comments

Popular posts from this blog